Targeting Protein Tyrosine Phosphatases for Anticancer Drug Discovery

Author(s): Latanya M. Scott, Harshani R. Lawrence, Said M. Sebti, Nicholas J. Lawrence, Jie Wu

Journal Name: Current Pharmaceutical Design

Volume 16 , Issue 16 , 2010

Become EABM
Become Reviewer
Call for Editor


Protein tyrosine phosphatases (PTPs) are a diverse family of enzymes encoded by 107 genes in the human genome. Together with protein tyrosine kinases (PTKs), PTPs regulate various cellular activities essential for the initiation and maintenance of malignant phenotypes. While PTK inhibitors are now used routinely for cancer treatment, the PTP inhibitor development field is still in the discovery phase. In this article, the suitability of targeting PTPs for novel anticancer drug discovery is discussed. Examples are presented for PTPs that have been targeted for anticancer drug discovery as well as potential new PTP targets for novel anticancer drug discovery.

Keywords: Protein tyrosine phosphatase inhibitor, Shp2, PTP1B, Cdc14, PRL-3, LMW-PTP, Cdc25, eya

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Published on: 01 March, 2012
Page: [1843 - 1862]
Pages: 20
DOI: 10.2174/138161210791209027
Price: $65

Article Metrics

PDF: 55